ReviewJournal of Brown hospital medicine2026
Comprehensive Framework of Heart Failure with Preserved Ejection Fraction Management for Hospitalists: A Scoping Review.
Review in Journal of Brown hospital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and remains a major source of morbidity and hospitalization, particularly among older adults with multiple comorbidities. HFpEF is characterized by diastolic dysfunction, ventricular stiffness, and impaired filling, driven by systemic inflammation, endothelial dysfunction, and myocardial fibrosis. Management is complicated by common comorbidities such as hypertension, type 2 diabetes, atrial fibrillation, chronic kidney disease, obesity, and coronary artery disease. Recent advances have expanded treatment options, with sodium-glucose cotransporter-2 (SGLT2) inhibitors demonstrating the strongest evidence for reducing heart failure hospitalizations and cardiovascular death. Additional therapies, including angiotensin receptor-neprilysin inhibitors (ARNIs), non-steroidal mineralocorticoid receptor antagonists (e.g., finerenone), and glucagon-like peptide-1 (GLP-1) receptor agonists, show promise in selected populations. Hospitalists play a critical role in early recognition, initiation of GDMT, and comprehensive management of comorbidities. This review aims to summarize current guideline-directed medical therapy (GDMT) for HFpEF and provide a practical framework for hospital-based management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.